Newsfeed: UC San Diego Sulpizio Cardiovascular Center Program Receives National Recognition
Newsfeed: United Therapeutics awaits FDA decision on oral PAH drug as Sandoz seeks generic approval
Newsfeed: Gene regulation found to play role in pulmonary hypertension
Newsfeed: Breakthrough could help sufferers of fatal lung disease
Newsfeed: CPAP in EMS
Alert: PHA Canada statement regarding FDA revatio decision
The U.S. Food and Drug Administration (FDA) has issued a decision regarding sildenafil (Revatio) for pediatric usage. More information can be found in FDA’s Medwatch and Pfizer’s statements. Based on an interpretation of the same study used in the FDA's decision, the European Medicines Agency has approved the use of sildenafil (Revatio) in children. PHA Canada’s Medical Advisory Committee in conjunction with pediatric PH specialists across …
Newsfeed: Yard Sale for Pulmonary Hypertension
Alert: Ontario Tracleer
Attention patients living in Ontario taking Tracleer: Actelion Pharmaceuticals has informed us there is a technical error in the ODB drug approval system. When patients fill a prescription of Tracleer or any generic of Tracleer in Ontario only, pharmacists try to get approval for coverage through the system, they are being rejected because those drugs gave been accidentally deleted from the approval list. The ODB has acknowledged this error an…
Newsfeed: Exercise training for pulmonary hypertension: another prescription to write?
For over 30 years I have been advising my patients with pulmonary hypertension (PH) to be physically active to a level of exertion that does not produce severe dyspnoea persisting post-exercise, dizziness, syncope or chest pain, based on the assumption that inactivity was bad both physically and mentally. This empirical advice meant little in the years before effective medical and surgical methods of treating PH were developed, but gained importa…
Newsfeed: Daughter Collects Pennies for Mom
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter